Causality assessment strategies and methods for Chinese medicines-induced liver injury / 药学学报
Acta Pharmaceutica Sinica
; (12): 920-928, 2018.
Article
de Zh
| WPRIM
| ID: wpr-779952
Bibliothèque responsable:
WPRO
ABSTRACT
Chinese medicines (CM)-induced liver injury is one of the severe adverse drug reactions (ADRs) in clinical application, which restricts new drug research and development (R&D), clinical safe usage and industry development of CM. The issue, to elucidate the causality between liver injury and CM, is either a globally challenging problem or the precondition of CM safety evaluation. However, owing to the complexicity of CM and various influencing factors to CM-induced liver injury, the causality assessment for CM is much difficult, compared to synthetic drugs. Besides, the current assessment methods, primarily designed for clinical diagnosis, are difficult to be used in new drug R&D of CM. Hereinto, we reviewed the current ADR causality methods and proposed a new strategy called integrated evidence chain-based causality assessment method for CM-induced liver injury. The new causality method is designed for new drug R&D based on the complexicity of CM, to provide methodology in scientific assessment of causality of CM-induced liver injury and to promote success rate of new drug R&D. The new method could also raise our ability to find, avoid and prevent the risk of CM-induced liver injury.
Texte intégral:
1
Base de données:
WPRIM
Type d'étude:
Etiology_studies
Langue:
Zh
Journal:
Acta Pharmaceutica Sinica
Année:
2018
Type de document:
Article